Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 28, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

797

What's New in Psoriasis.

Stephanie von Csiky-Sessoms1, Mark Lebwohl1

  • 1The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, 5th Floor, New York, NY 10029, USA.

Dermatologic Clinics
|March 10, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.

The Journal of dermatology·2026
Same author

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

JAMA dermatology·2026
Same author

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial.

Dermatology and therapy·2026
Same author

The Misdiagnosis of Pemphigus Foliaceus as Psoriasis.

International journal of dermatology·2026
Same author

Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel.

Journal of drugs in dermatology : JDD·2026
Same journal

The Evidence Is In: Devices and Biologics Reshaping Modern Dermatology.

Dermatologic clinics·2026
Same journal

Energy-Based Devices for Body Contouring.

Dermatologic clinics·2026
Same journal

Microfocused Ultrasound with Visualization for Skin Tightening: Clinical Applications, Safety, and Technical Considerations.

Dermatologic clinics·2026
Same journal

Devices in Onychomycosis: A Status Update.

Dermatologic clinics·2026
Same journal

Acne Laser Devices in Dermatology.

Dermatologic clinics·2026
Same journal

Fractional Laser Therapy for Androgenetic Alopecia: Mechanisms, Clinical Evidence, and Practical Implementation.

Dermatologic clinics·2026
See all related articles

Psoriasis management has advanced with new biologic medications targeting key inflammatory cytokines. These treatments offer improved quality of life for patients with this common chronic skin condition.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Psoriasis is a prevalent, chronic inflammatory skin disease affecting 2.2% of the US population.
  • Characterized by erythematous plaques, psoriasis significantly impacts patients' quality of life.
  • Proinflammatory cytokines are central to the pathogenesis of psoriatic disease.

Purpose of the Study:

  • To summarize recent advancements in psoriasis management.
  • To review current and emerging treatment options for psoriatic disease.
  • To highlight the role of biologic therapies targeting specific cytokines.

Main Methods:

  • Review of recent scientific literature on psoriasis management.
  • Analysis of clinical studies on biologic medications.
Keywords:
BiologicInterleukin-17Interleukin-23PsoriasisTNF-αTreatment

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K
SCAnED - An Open-source Skin Segmentation Macro for Semi-automated Cell and Nuclei Detection in Epidermal and Dermal Skin Compartments
06:34

SCAnED - An Open-source Skin Segmentation Macro for Semi-automated Cell and Nuclei Detection in Epidermal and Dermal Skin Compartments

Published on: August 8, 2025

548

Related Experiment Videos

Last Updated: Jan 28, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

797
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K
SCAnED - An Open-source Skin Segmentation Macro for Semi-automated Cell and Nuclei Detection in Epidermal and Dermal Skin Compartments
06:34

SCAnED - An Open-source Skin Segmentation Macro for Semi-automated Cell and Nuclei Detection in Epidermal and Dermal Skin Compartments

Published on: August 8, 2025

548
  • Synthesis of data on cytokine-targeted therapies.

    • Main Results:

    • Significant progress has been made in understanding psoriasis pathogenesis.
    • Biologic medications targeting key proinflammatory cytokines have shown efficacy.
    • New treatment options are expanding therapeutic strategies for psoriasis.

    Conclusions:

    • Recent findings underscore the importance of cytokine-targeted therapies in psoriasis.
    • Advances in biologic medications offer improved management options.
    • Continued research is vital for optimizing psoriasis treatment and patient outcomes.